• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与 Budd-Chiari 综合征相关的肝细胞癌:影像学特征和经导管动脉化疗栓塞。

Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization.

机构信息

Department of Interventional Radiology, Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China.

出版信息

BMC Gastroenterol. 2013 Jun 24;13:105. doi: 10.1186/1471-230X-13-105.

DOI:10.1186/1471-230X-13-105
PMID:23800233
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3693971/
Abstract

BACKGROUND

Budd-Chiari syndrome (BCS) often leads to hepatocellular carcinoma (HCC). Transcatheter arterial chemoembolization (TACE) has been increasingly used to treat BCS patients with HCC. The purposes of this study were to illustrate imaging features in BCS patients with HCC, and to analyze the effects of TACE on BCS patients with HCC.

METHODS

246 consecutive patients with primary BCS were retrospectively studied. 14 BCS patients with HCC were included in this study. BCS were treated with angioplasty and/or stenting, and HCC were managed with TACE. Imaging features on ultrasonography, CT, MRI, and angiography and the serum AFP level were analyzed.

RESULTS

Inferior vena cava block and stricture of hepatic venous outflow tract more frequently occurred. Portal vein invasion was found in only 2 patients (14.2%). Imaging studies showed that most nodules of HCC were near the edge of liver, irregular, more than 3 cm in diameter, heterogeneous mass and solitary (≤3 nodules). HCC in patients associated with BCS was isointense or hypointense in nonenhanced CT images, and exhibited heterogeneous enhancement during the arterial phase and washout during the portal venous phase on enhanced CT and MRI. The serum AFP level significantly declined after TACE treatment.

CONCLUSIONS

BCS patients with inferior vena cava block and stricture of hepatic venous outflow tract seems to be associated with HCC. A single, large, irregular nodule with a peripheral location appears to be HCC. TACE can effectively treat HCC in BCS patients.

摘要

背景

布加综合征(BCS)常导致肝细胞癌(HCC)。经导管动脉化疗栓塞(TACE)已越来越多地用于治疗合并 HCC 的 BCS 患者。本研究旨在阐述合并 HCC 的 BCS 患者的影像学特征,并分析 TACE 对合并 HCC 的 BCS 患者的疗效。

方法

回顾性分析 246 例原发性 BCS 患者,其中 14 例 BCS 合并 HCC 患者纳入本研究。BCS 患者接受血管成形术和/或支架置入治疗,HCC 患者接受 TACE 治疗。分析超声、CT、MRI 和血管造影的影像学特征及血清 AFP 水平。

结果

下腔静脉阻塞和肝静脉流出道狭窄更为常见。仅 2 例(14.2%)患者存在门静脉侵犯。影像学研究显示,HCC 结节多位于肝脏边缘,形态不规则,直径>3cm,呈混杂密度,单发(≤3 个结节)。与 BCS 相关的 HCC 在平扫 CT 上呈等或稍低信号,增强 CT 和 MRI 动脉期呈不均匀强化,门静脉期呈洗脱。TACE 治疗后血清 AFP 水平显著下降。

结论

下腔静脉阻塞和肝静脉流出道狭窄的 BCS 患者似乎与 HCC 相关。单发、大、形态不规则、边缘分布的结节提示 HCC。TACE 可有效治疗 BCS 合并 HCC 患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb46/3693971/f05fe37de306/1471-230X-13-105-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb46/3693971/1e67814db77f/1471-230X-13-105-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb46/3693971/544af34d01ea/1471-230X-13-105-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb46/3693971/f05fe37de306/1471-230X-13-105-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb46/3693971/1e67814db77f/1471-230X-13-105-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb46/3693971/544af34d01ea/1471-230X-13-105-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb46/3693971/f05fe37de306/1471-230X-13-105-3.jpg

相似文献

1
Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization.与 Budd-Chiari 综合征相关的肝细胞癌:影像学特征和经导管动脉化疗栓塞。
BMC Gastroenterol. 2013 Jun 24;13:105. doi: 10.1186/1471-230X-13-105.
2
Characteristics of hepatocellular carcinoma in Egyptian patients with primary Budd-Chiari syndrome.埃及原发性布加综合征患者肝细胞癌的特征。
Liver Int. 2017 Mar;37(3):415-422. doi: 10.1111/liv.13219. Epub 2016 Sep 13.
3
Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors.布加综合征中的肝细胞癌:特征与危险因素
Gut. 2008 Jun;57(6):828-35. doi: 10.1136/gut.2007.139477. Epub 2008 Jan 24.
4
Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE.肝细胞癌合并下腔静脉膜性阻塞:发生率、特征、危险因素和 TACE 的临床疗效。
Radiology. 2010 Feb;254(2):617-26. doi: 10.1148/radiol.09090738.
5
Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.不可切除肝细胞癌患者行三药经肝动脉化疗栓塞术获益的预测因素。
Cancer Med. 2019 Aug;8(9):4200-4213. doi: 10.1002/cam4.2355. Epub 2019 Jun 17.
6
Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome.在伴有布加综合征的患者中,表现为动脉期强化的结节中,洗脱低特异性诊断肝细胞癌。
J Hepatol. 2019 Jun;70(6):1123-1132. doi: 10.1016/j.jhep.2019.01.009. Epub 2019 Jan 14.
7
Hepatocellular carcinoma in Budd-Chiari syndrome: enhancement patterns at dynamic gadolinium-enhanced T1-weighted MR imaging.布加综合征中的肝细胞癌:动态钆增强T1加权磁共振成像的强化模式
Cell Biochem Biophys. 2014 Sep;70(1):661-6. doi: 10.1007/s12013-014-9970-z.
8
Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.表阿霉素在球囊阻断经导管动脉化疗栓塞治疗肝细胞癌中的疗效优于米铂。
Oncology. 2019;96(2):79-86. doi: 10.1159/000492822. Epub 2018 Oct 5.
9
Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.经肝动脉化疗栓塞治疗后 AFP 状态对肝细胞癌结局的预后意义。
Ann Surg Oncol. 2012 Oct;19(11):3540-6. doi: 10.1245/s10434-012-2368-5. Epub 2012 Apr 25.
10
Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.经导管动脉化疗栓塞(TACE)后先前的化疗栓塞反应可预测复发性肝细胞癌患者后续使用米立膦酸 TACE 的抗肿瘤效果。
Oncology. 2011;80(3-4):188-94. doi: 10.1159/000328749. Epub 2011 Jun 27.

引用本文的文献

1
Role of Vascular Liver Diseases in Hepatocellular Carcinoma Development.血管性肝病在肝细胞癌发生中的作用。
Cancers (Basel). 2025 Jun 20;17(13):2060. doi: 10.3390/cancers17132060.
2
Clinical profile and outcomes of hepatocellular carcinoma in primary Budd-Chiari syndrome.原发性布加综合征合并肝细胞癌的临床特征及预后
World J Gastrointest Oncol. 2024 Mar 15;16(3):699-715. doi: 10.4251/wjgo.v16.i3.699.
3
Differentiation between small hepatocellular carcinoma (<3 cm) and benign hepatocellular lesions in patients with Budd-Chiari syndrome: the role of multiparametric MR imaging.

本文引用的文献

1
Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE.肝细胞癌合并下腔静脉膜性阻塞:发生率、特征、危险因素和 TACE 的临床疗效。
Radiology. 2010 Feb;254(2):617-26. doi: 10.1148/radiol.09090738.
2
Primary Budd-Chiari syndrome.原发性布加综合征
J Hepatol. 2009 Jan;50(1):195-203. doi: 10.1016/j.jhep.2008.10.007. Epub 2008 Oct 26.
3
Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors.
布加综合征患者中小肝细胞癌(<3 cm)与良性肝细胞病变的鉴别:多参数磁共振成像的作用
Front Oncol. 2023 Nov 21;13:1282181. doi: 10.3389/fonc.2023.1282181. eCollection 2023.
4
Budd-Chiari Syndrome Imaging Diagnosis: State of the Art and Future Perspectives.布加综合征的影像学诊断:现状与未来展望
Diagnostics (Basel). 2023 Jul 3;13(13):2256. doi: 10.3390/diagnostics13132256.
5
Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis.布加综合征及其相关肝细胞癌:临床危险因素及潜在免疫治疗获益分析
Front Oncol. 2022 Dec 8;12:1075685. doi: 10.3389/fonc.2022.1075685. eCollection 2022.
6
Budd-Chiari Syndrome Management: Controversies and Open Issues.布加综合征的管理:争议与未决问题
Diagnostics (Basel). 2022 Nov 3;12(11):2670. doi: 10.3390/diagnostics12112670.
7
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).布加综合征:亚太肝病学会(APASL)的共识指南。
Hepatol Int. 2021 Jun;15(3):531-567. doi: 10.1007/s12072-021-10189-4. Epub 2021 Jul 8.
8
Epidemiology, pathogenesis, diagnosis, surveillance, and management of hepatocellular carcinoma associated with vascular liver disease.血管性肝病相关肝细胞癌的流行病学、发病机制、诊断、监测和管理。
Kaohsiung J Med Sci. 2021 May;37(5):355-360. doi: 10.1002/kjm2.12368. Epub 2021 Mar 2.
9
Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon.肝脂肪酸结合蛋白缺陷型肝细胞腺瘤的恶性转化:一种罕见现象的组织病理学谱。
Mod Pathol. 2020 Apr;33(4):665-675. doi: 10.1038/s41379-019-0374-x. Epub 2019 Sep 30.
10
Hepatocellular nodules in vascular liver diseases.血管性肝脏疾病中的肝细胞结节。
Virchows Arch. 2018 Jul;473(1):33-44. doi: 10.1007/s00428-018-2373-6. Epub 2018 May 26.
布加综合征中的肝细胞癌:特征与危险因素
Gut. 2008 Jun;57(6):828-35. doi: 10.1136/gut.2007.139477. Epub 2008 Jan 24.
4
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.肝硬化中直径20毫米及以下肝脏结节的诊断:肝细胞癌无创诊断标准的前瞻性验证
Hepatology. 2008 Jan;47(1):97-104. doi: 10.1002/hep.21966.
5
Budd-Chiari syndrome: etiology, pathogenesis and diagnosis.布加综合征:病因、发病机制与诊断
World J Gastroenterol. 2007 May 21;13(19):2693-6. doi: 10.3748/wjg.v13.i19.2693.
6
Budd-Chiari syndrome: spectrum of imaging findings.布加综合征:影像学表现谱
AJR Am J Roentgenol. 2007 Feb;188(2):W168-76. doi: 10.2214/AJR.05.0168.
7
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.对8510例无法切除的肝细胞癌患者进行经动脉化疗栓塞术的前瞻性队列研究。
Gastroenterology. 2006 Aug;131(2):461-9. doi: 10.1053/j.gastro.2006.05.021.
8
Management of hepatocellular carcinoma.肝细胞癌的管理
Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.
9
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients.肝细胞癌患者的生存率:389例患者的回顾性分析
Br J Cancer. 2005 May 23;92(10):1862-8. doi: 10.1038/sj.bjc.6602590.
10
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.肝硬化中的肝细胞癌:发病率及危险因素
Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50. doi: 10.1053/j.gastro.2004.09.014.